PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of f1000resSubmitAuthor GuidelinesAboutAdvisory PanelF1000ResearchView this article
 
Version 2. F1000Res. 2016; 5: 2667.
Published online 2017 August 31. doi:  10.12688/f1000research.9472.2
PMCID: PMC5590079
Other versions

Case Report: Whole exome sequencing identifies a novel frameshift insertion c.1325dupT (p.F442fsX2) in the tyrosine kinase domain of BTK gene in a young Indian individual with X-linked agammaglobulinemia

Amit Rawat, Investigation, Writing – Review & Editing,#1 Shamsudheen Karuthedath Vellarikkal, Data Curation, Methodology, Validation, Writing – Original Draft Preparation,#2,3 Ankit Verma, Data Curation, Methodology, Validation, Writing – Original Draft Preparation,#3 Rijith Jayarajan, Data Curation, Methodology, Validation,3 Anju Gupta, Investigation,1 Surjit Singh, Investigation,1 Anita Chopra, Investigation,4 Rajive Kumar, Investigation,4 Vinod Scaria, Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing,a,2,5 and Sridhar Sivasubbu, Conceptualization, Funding Acquisition, Resources, Writing – Review & Editingb,2,3

Abstract

X-linked agammaglobulinemia (XLA) is an extremely rare inherited primary immunodeficiency characterized by recurrent bacterial infections, decrease in number of mature B cells and low serum immunoglobulins. XLA is caused by mutations in the gene encoding Bruton's tyrosine kinase. We report a case of a young Indian boy suspected to have XLA. Immunophenotyping was performed for the affected child using CD20, CD19 and CD3 antibodies. Whole exome sequencing was performed using trio-based approach. The variants were further analyzed using capillary sequencing in the trio as well as maternal grandmother. Initial immunophenotyping in the affected child showed decreased count of CD19+ B cells. To strengthen the clinical findings and confirm the diagnosis of XLA, we performed whole exome sequencing. Our analysis identified a novel frameshift insertion (c.1325dupT) in the BTK gene, which was further validated by Sanger sequencing. Our approach shows the potential in using whole exome sequencing to pinpoint the molecular lesion, enabling timely diagnosis and genetic counseling, and potentially offering prenatal genetic testing for the family.

Keywords: X-linked agammaglobulinemia, Bruton's tyrosine kinase, Whole exome sequencing, Flow cytometry, B-lymphocytes

Introduction

Primary immunodeficiencies are congenital defects in the immune defence mechanisms of the host against invading pathogens. X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder (OMIM# 300755) characterized by recurrent infections causing pneumonia, conjunctivitis, gastrointestinal infections, otitis media and sinopulmonary infections 1, which may require frequent hospitalization. The disease is extremely rare with an estimated prevalence of 3–6 per 1,000,000 males 2 and is inherited in an X-linked recessive manner. The disease arises from genetic defects, due to which the mature B lymphocytes are either low in number or completely absent in the bloodstream while also exhibiting a complete absence of serum immunoglobulins 1. The absence of immunoglobulins results in a compromised humoral immune response, which makes the affected individual extremely vulnerable to infections with encapsulated bacteria and enteroviruses. Molecular genetic studies have conclusively mapped the genetic locus of XLA to the gene encoding for the Bruton’s tyrosine kinase (BTK) 3. A comprehensive mutation database (BTKbase) lists over 700 unique mutations associated with XLA that affect the activity of BTK protein 4.

Case report

A five year old boy of north Indian origin, born out of a non-consanguineous marriage ( Figure 1A) presented to the hospital with headache, fever and a history of recurrent infections requiring hospitalization. The antenatal and perinatal periods were uneventful. His clinical history revealed that the child had been hospitalized for septicaemia and underwent treatment with intravenous (IV) antibiotics for 2 weeks at one year of age. Later, at 2.5 years, the child developed fever with swelling in right knee joint that was diagnosed as septic arthritis. The child was again hospitalized at 5 years of age for pyogenic meningitis. The culture of cerebrospinal fluid was found to be positive for Pseudomonas aeruginosa. On close examination, the tonsils were found to be absent and there was no peripheral lymphadenopathy. The immunoglobulin profile revealed serum level of IgG 50 mg/dl (200–700 mg/dl), IgA 5 mg/dl (40–200 mg/dl) and IgM 9 mg/dl (50–200 mg/dl). The hemogram showed hemoglobin concentration of 9.5 g/dl (11.5–15.5 g/dl), total leukocyte count 14800/cumm (6000–13500/cumm), platelet count 931000/cumm (150000–400000/cumm) and erythrocyte sedimentation rate ESR 18mm/1st hr (0–14 mm/1st hr).

Figure 1.
A). Pedigree of the family B). Flow cytometric immunophenotyping of peripheral blood lymphocytes gated on side scatter/CD45 plot. In CD19/CD3 plot, arrow depicts the count of B lymphocytes (CD19+) and T lymphocytes (CD3+). C). Flow cytometric estimation ...

The blood flow cytometric analysis of the affected child was performed to evaluate the status and count of mature B cells. The patient (III.1) has only CD3+ lymphocytes as observed on CD19/CD3 dot plot and there was complete absence of CD19+ cells (0.02%) ( Figure 1B). The staining for BTK protein on CD14+ monocytes showed decreased (20.71%) expression of BTK in proband as compared to control (72.07%) ( Figure 1C). This observation was consistent with the diagnosis of XLA 5. The patient had no family history of immunodeficiency and no such characteristics were present in any other family members.

The blood samples were collected and processed for genomic DNA isolation by salting out method 6. We performed the whole exome sequencing using trio-based approach (patient, mother and father). In brief, the whole-exome library was prepared using Nextera rapid capture expanded exome kit (Illumina Inc., USA) according to manufacturer’s standard protocol. Sequencing was performed on Illumina Hiseq2500 platform (Illumina Inc., USA) with 130bp paired-end reads. Reads were trimmed using Trimmomatic v0.33 7 and aligned to reference genome hg19 (GRCh37) by Stampy v1.0.23 8 along with BWA v0.7.12-r1039 9. PCR duplicates were marked using Picard tools v1.127. Variations were called using Platypus v0.7.9 10 and annotated using ANNOVAR 11. Analysis revealed a novel frameshift insertion c.1325dupT in exon 14 of the BTK gene. The mutation was found to be homozygous in child and heterozygous in mother. The identified mutation c.1325dupT has not yet been reported in the BTKbase 4 and absent in ExAC, 1000genome as well as internal control databases from South Asia and Middle East ( http://clingen.igib.res.in/almena), which confirms the novelty of the variation. The mutation evaluation by SIFT Indel tool ( http://sift.bii.a-star.edu.sg/www/SIFT_indels2.html, 12) was predicted to be damaging and caused nonsense mediated decay (confidence score 0.858). Further in silico analysis suggested that the mutation causes Isoleucine at 443 residue in BTK to be replaced by Histidine and introduces a premature stop codon at 444 residue, which lies in the kinase domain of the BTK protein ( Figure 1D).

The variation was further validated by PCR amplification of region encompassing the variation using specific primer sets (Forward primer: 5’-CCCCAAATGCTACTGAGATGGT-3’ and Reverse primer: 3’-CCTATTTCTACCCCAGTAGGGA-5’) with the annealing temperature of 59°C using Brazilian taq polymerase (Invitrogen, USA) according to manufacturer instruction. PCR products were purified using Qiaquick PCR purification kit (QIAGEN, Germany). Capillary sequencing was performed using BigDye-terminator chemistry on 3130xl Genetic Analyzer (Applied Biosystems, USA). Analysis revealed that the mutation was homozygous in child (III.1), heterozygous in mother (II.3) and absent in father (II.2) and maternal grandmother (I.4) ( Figure 1E).

Discussion

XLA is a primary immunodeficiency disorder characterized by recurrent infections causing pneumonia, conjunctivitis, gastrointestinal infections, otitis media and sinopulmonary infections 1. Whole exome sequencing has been increasingly used to identify mutations in rare genetic diseases mainly due to the speed, cost and amenability as compared to traditional capillary sequencing 13. Recent reports have suggested the application of whole exome sequencing for mutation detection in a variety of primary immunodeficiency cases 14, 15.

In the present report, we performed whole exome sequencing using a trio-based approach for a child from an Indian family who presented to the clinic with the suspected diagnosis of XLA. The lack of readily available specific gene sequencing assays coupled with absence of a next-generation sequences (NGS) based targeted gene panels for XLA provided the impetus for attempting exome sequencing.

Our exome sequencing analysis revealed a novel frameshift insertion c.1325dupT in exon 14 of the BTK gene. The mutation was found to be homozygous in patient and heterozygous in unaffected mother, which was further validated by capillary sequencing. This confirmed the X-linked inheritance and carrier status of the mother for the mutation. The mutation was found to be absent in unaffected father and maternal grandmother. The identified mutation c.1325dupT was found to be novel and damaging due to truncation of the BTK at 444 residue of kinase domain. The flow cytometric analysis for BTK stained monocytes shows decreased expression of BTK in proband as compared to control ( Figure 1C). The mutation excludes functionally well characterized active site residue Y551 of the protein. Additionally, nonsense mutation at the codon Y425X, E441X, Q459X and Q497X is known to cause loss of kinase activity of BTK, which has been previously demonstrated using in vitro kinase activity assay in Japanese individuals 16. Since c.1325dupT (p.F442fsX2) lies in the vicinity of the above mentioned well studied codon positions, the effect of the mutation is expected to be damaging to BTK. Currently the patient is on intravenous immunoglobulin replacement therapy (15 g every 3–4 weekly) and is responding well. We could not avail the RNA samples to perform transcript analysis or functional studies.

In summary, our flow cytometry data and exome sequencing analysis are well correlated for confirming the diagnosis of XLA. The outcome from the present study strongly supports the pathogenicity of identified novel mutation in BTK gene.

Consent

Written informed consent was obtained the parents of the child.

Data availability

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2017 Rawat A et al.

The raw sequencing data are available at NCBI Sequence Read Archive ( http://www.ncbi.nlm.nih.gov/sra) with accession number SRR3439009.

Acknowledgement

Authors also acknowledge Ms. Rowmika Ravi and Vigneshwar Senthivel for proofreading and the GUaRDIAN consortium for support.

Notes

[version 2; referees: 2 approved]

Funding Statement

SS and VS acknowledge funding from the Council of Scientific and Industrial Research (CSIR), India through Grant No. BSC0212.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Notes

Revised. Amendments from Version 1

The updated version of the manuscript has incorporated the reviewer's suggestions, a revised Figure 1, and patient's BTK expression profile.

References

1. Ochs HD, Smith CI.: X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore). 1996;75(6):287–99. 10.1097/00005792-199611000-00001 [PubMed] [Cross Ref]
2. Conley ME.: B cells in patients with X-linked agammaglobulinemia. J Immunol. 1985;134(5):3070–4. [PubMed]
3. Tsukada S, Saffran DC, Rawlings DJ, et al. : Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279–90. 10.1016/0092-8674(93)90667-F [PubMed] [Cross Ref]
4. Väliaho J, Smith CI, Vihinen M.: BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006;27(12):1209–17. 10.1002/humu.20410 [PubMed] [Cross Ref]
5. Conley ME, Broides A, Hernandez-Trujillo V, et al. : Genetic analysis of patients with defects in early B-cell development. Immunol Rev. 2005;203(1):216–34. 10.1111/j.0105-2896.2005.00233.x [PubMed] [Cross Ref]
6. Miller SA, Dykes DD, Polesky HF.: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. 10.1093/nar/16.3.1215 [PMC free article] [PubMed] [Cross Ref]
7. Bolger AM, Lohse M, Usadel B.: Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20. 10.1093/bioinformatics/btu170 [PMC free article] [PubMed] [Cross Ref]
8. Lunter G, Goodson M.: Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 2011;21(6):936–9. 10.1101/gr.111120.110 [PubMed] [Cross Ref]
9. Li H, Durbin R.: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589–95. 10.1093/bioinformatics/btp698 [PMC free article] [PubMed] [Cross Ref]
10. Rimmer A, Phan H, Mathieson I, et al. : Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet. 2014;46(8):912–8. 10.1038/ng.3036 [PMC free article] [PubMed] [Cross Ref]
11. Wang K, Li M, Hakonarson H.: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. 10.1093/nar/gkq603 [PMC free article] [PubMed] [Cross Ref]
12. Hu J, Ng PC.: SIFT Indel: predictions for the functional effects of amino acid insertions/deletions in proteins. PLoS One. 2013;8(10):e77940. 10.1371/journal.pone.0077940 [PMC free article] [PubMed] [Cross Ref]
13. Boycott KM, Vanstone MR, Bulman DE, et al. : Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–91. 10.1038/nrg3555 [PubMed] [Cross Ref]
14. Angulo I, Vadas O, Garcon F, et al. : Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–71. 10.1126/science.1243292 [PMC free article] [PubMed] [Cross Ref]
15. Lucas CL, Kuehn HS, Zhao F, et al. : Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97. 10.1038/ni.2771 [PMC free article] [PubMed] [Cross Ref]
16. Hashimoto S, Tsukada S, Matsushita M, et al. : Identification of Bruton’s tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. Blood. 1996;88(2):561–73. [PubMed]

Review Summary Section

Review dateReviewer name(s)Version reviewedReview status
2017 September 7Saharuddin Bin MohamadVersion 2Approved
2017 February 10Saharuddin Bin MohamadVersion 1Approved with Reservations
2017 January 20Mohamed Badawy Hassan Tawfik Abdel-NaserVersion 1Approved

Approved

1Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
Competing interests: No competing interests were disclosed.
Review date: 2017 September 7. Status: Approved

I am satisfied with the corrections and comments made by the authors.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Approved with Reservations

1Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
Competing interests: No competing interests were disclosed.
Review date: 2017 February 10. Status: Approved with Reservations

XLA is a rare disease which gave this case report high value for being indexed. However I have some concerns regarding the report as below:

  1. Since the patient was suspected with XLA and BTK gene is well known as the cause of the condition. Why Whole Exome Sequencing (WES) was conducted for this case? Why not conduct targeted sequencing for BTK since that would be much cheaper and easier to analyse. Since WES was conducted, I think authors should provide other results from WES analysis such as variant analysis, etc.
  2. The results in Figure 1D for heterogeneous needs further explanation. It seems like the heterogeneous is not having two peaks at the asterisks position, but having two peaks at 5 positions downstream to the asterisks.
  3. I would like to suggest evidence to be provided for the truncated BTK gene due to the mutation (Reverse transcriptase-PCR).
  4. I would like to suggest the authors to referred to other database with bigger number of samples such as Exome Aggregation Consortium and 1000 Genomes database (not only BTKbase).

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Approved

1Faculty of Medicine, Ain Shams University, Cairo, Egypt
Competing interests: No competing interests were disclosed.
Review date: 2017 January 20. Status: Approved

  • The case report is interesting. 
  • The authors unnecessarily repeated several sentences and phrases e.g. in the Introduction section the sentence "X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder ...." has been repeated in the discussion section. Also, in the case report section the phrase "of the right knee joint". 
  • The findings of the whole exome sequencing analysis should be regarded as interesting findings because a causal relationship with X-linked agammaglobulinemia needs additional cases and animal studies.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.


Articles from F1000Research are provided here courtesy of F1000 Research Ltd